Trastuzumab-emtansina versus otros regímenes anti-HER-2 en el cáncer de mama HER-2 positivo precoz o irresecable o metastásico: revisión sistemática y metaanálisis en red
DOI:
https://doi.org/10.17843/rpmesp.2024.411.13351Palabras clave:
Genes HER-2, Cáncer de Mama, Metaanálisis en Red, Revisión Sistemática, Trastuzumab EmtansinaResumen
Objetivo. Nuestro objetivo fue estudiar la eficacia y la seguridad de trastuzumab-emtansina (T-DM1) en comparación con otras terapias anti-HER-2 en el cáncer de mama (CM) HER-2 positivo. Materiales y métodos. Realizamos un metaanálisis de red (NMA, por sus siglas en inglés) de ensayos clínicos aleatorizados (ECA). Nuestro estudio se centró en pacientes sometidos al
tratamiento para el cáncer de mama localmente avanzado no resecable (CMLA) o cáncer de mama metastásico (CMm), que incluía esquemas con trastuzumab y taxanos. Además, consideramos casos dentro de los primeros 6 meses de tratamiento para
el cáncer de mama temprano (CMT) HER-2 positivo. Resultados. Se incluyeron en nuestro análisis un total de 23 ECA y 41 reportes. En CMLA y CMm, no se observaron diferencias estadísticamente significativas en ninguna de las comparaciones entre T-DM1 y otras terapias anti-HER-2 positivo. Al evaluar la sobrevida libre de progresión (SLP), trastuzumab-deruxtecan (T-DXd)
y PyroCap demostraron una mayor eficacia en comparación con otros tratamientos (Hazard Ratio [HR]: 3,57; intervalo de confianza al 95% [IC 95%]: 2,75-4,63 y HR: 1.82; IC 95%: 1,35-2,44; respectivamente), mientras que T-DM1 por sí solo mostró una efectividad superior en comparación con LapCap (HR: 0,65; IC 95%: 0,55-0,77), TrasCap (HR: 0,65; IC 95%: 0,46-0,91), Lap-
CapCitu (HR: 0,60; IC 95%: 0,33-1,1), Nera (HR: 0,55; IC 95%: 0,39-0,77) y Cap (HR: 0,37; IC 95%: 0,28-0,49). Conclusiones. Este NMA estableció un ranking basado en la eficacia y seguridad comparativas entre las intervenciones disponibles. Aunque superior a otros esquemas, T-DM1 mostró una menor eficacia en la SLP y la tasa de respuesta objetiva, y una tendencia hacia una
sobrevida global peor que T-DXd.
Descargas
Referencias
International Agency for Research on Cancer. World Health Organization [Internet]. [citado el 10 de febrero de 2023]. Global Cancer
Observatory. Globocan. Disponible en: https://gco.iarc.fr/
Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice
guideline update. J Clin Oncol. 2013;31(31):3997-4013. doi: 10.1200/JCO.2013.50.9984.
Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Semin Cancer Biol. 1999;9(2):125-38. doi: 10.1006/scbi.1998.0083. PMID: 10202134.
Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990;8(1):103-12. doi: 10.1200/JCO.1990.8.1.103.
Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. Association of c-erbB-2 protein over-expression with high rate of cell
proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer. 1991;49(5):650-5. doi: 10.1002/ijc.2910490504. PMID: 1682277.
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639-48. doi: 10.1200/JCO.1999.17.9.2639.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92. doi: 10.1056/NEJM200103153441101.
Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety
of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265-74. doi: 10.1200/JCO.2005.04.173.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable
HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84. doi: 10.1056/NEJMoa052122.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy
in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-72. doi: 10.1056/NEJMoa052306.
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer.
N Engl J Med. 2012;367(19):1783-91. doi: 10.1056/NEJMoa1209124.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617-628. doi: 10.1056/NEJMoa1814017.
Roche_Pharma_AG (2018) Perjeta® summary of product characteristics [Internet]. [citado el 1 de abril de 2019]. Disponible en:
https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf
Genentech_Inc. (2012) PERJETA prescribing information [Internet]. [citado el 1 de abril de 2019]. Disponible en: https ://www.acces sdata .fda.gov/drugs atfda docs/label /2012/12540 9lbl.pdf.
Novartis_Europharm_Ltd (2019) Tyverb summary of product characteristics [Internet]. [citado el 1 de abril de 2019]. Disponible en:
https ://www.ema.europ a.eu/en/docum ents/product-infor matio n/tyver b-epar-produ ct-infor matio n_en.pdf.
GlaxoSmithKline (2007) TYKERB prescribing information [Internet]. [citado el 1 de abril de 2019]. Disponible en: https://www.accesdata.fda.gov/drugs atfda docs/label /2010/022059s007 lbl.pdf.
Puma_Biotechnology_Inc. (2017) NERLYNX prescribing information [Internet]. [citado el 1 de abril de 2019]. Disponible en: https://www.acces sdata .fda.gov/drugs atfda docs/label2017/20805 1s000 lbl.pdf.
Puma_Biotechnology_Inc. (2018) Nerlynx® summary of product characteristics [Internet]. [citado el 1 de abril de 2019]. Disponible
en: https://www.ema.europ a.eu/en/docum ents/product-infor mation/nerly nx-epar-produ ct-infor matio n_en.pdf.
Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive
Metastatic Breast Cancer. N Engl J Med. 2020;382(7):597-609. doi: 10.1056/NEJMoa1914609.
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022;386(12):1143-1154. doi: 10.1056/NEJMoa2115022.
Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, et al. CEREBEL (EGF111438): A Phase III, Randomized,
Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth
Factor Receptor 2-Positive Metastatic Breast Cancer. J Clin Oncol. 2015;33(14):1564-73. doi: 10.1200/JCO.2014.57.1794.
Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007;110(5):965-72. doi: 10.1002/cncr.22885.
Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol. 2015;16(7):816-29. doi: 10.1016/S1470-2045(15)00051-0.
Paracha N, Reyes A, Diéras V, Krop I, Pivot X, Urruticoechea A. Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis. Breast Cancer Res Treat. 2020;180(3):597-609. doi: 10.1007/s10549-020-05577-7.
Chen F, Chen N, Lv Z, Li L, Cui J. Efficacy of second-line treatments for patients with advanced human epidermal growth factor receptor 2 positive breast cancer after trastuzumab-based treatment: a systematic review and bayesian network analysis. J Cancer. 2021;12(6):1687-1697. doi: 10.7150/jca.51845.
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions.
Wiley-Interscience; Wiley-Blackwell; 2019. 728 p.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.
Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777-84. doi: 10.7326/M14-2385.
Babineau J. Product Review: Covidence (Systematic Review Software). J Can Health Libr Assoc. 2014 Aug 1;35(2):68–71.
Covidence systematic review software. Veritas Health Innovation [Internet]. [citado el 1 de abril de 2019]. Disponible en: www.covidence.org
Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. Assessing risk of bias in a randomized trial [Internet]. Cochrane Handbook for
Systematic Reviews of Interventions. Wiley; 2019. p. 205–28. [citado el 1 de abril de 2019]. Disponible en: https://onlinelibrary.wiley.com/
doi: 10.1002/9781119536604.ch8
Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and
models for multi-arm studies. Res Synth Methods. 2012;3(2):98-110. doi: 10.1002/jrsm.1044.
Puhan MA, Schünemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349:g5630. doi: 10.1136/bmj.g5630.
Brignardello-Petersen R, Murad MH, Walter SD, McLeod S, Carrasco-Labra A, Rochwerg B, et al. GRADE approach to rate the certainty
from a network meta-analysis: addressing incoherence. J Clin Epidemiol. 2019;108:77-85. doi: 10.1016/j.jclinepi.2018.11.025.
Xu B, Yan M, Ma F, Hu X, Feng J, Ouyang Q, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of
HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol.
;22(3):351-360. doi: 10.1016/S1470-2045(20)30702-6.
Jiang Z, Yan M, Hu X, Zhang Q, Ouyang Q, Feng J, et al. Pyrotinib combined with capecitabine in women with HER2+ metastatic breast
cancer previously treated with trastuzumab and taxanes: A randomized phase III study. J Clin Orthod. 2019 May 20;37(15_suppl):1001–1001. doi: 10.1200/JCO.2019.37.15_suppl.1001.
Sim SH, Park IH, Jung KH, Kim SB, Ahn JH, Lee KH, et al. Abstract P6-17-23: Randomized phase II study of lapatinib plus vinorelbine
versus vinorelbine in patients with HER2 positive metastatic breast cancer progressed after lapatinib and trastuzumab treatment. Cancer Res. 2019 Feb 15;79(4_Supplement):P6–17 – 23–P6 – 17–23.
Ma F, Ouyang Q, Li W, Jiang Z, Tong Z, Liu Y, et al. Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/ or Trastuzumab: A Randomized, Phase II Study. JCO. 2019;37:2610-2619. doi: doi:
1200/JCO.19.00108.
Urruticoechea A, Rizwanullah M, Im SA, Ruiz ACS, Lang I, Tomasello G, et al. Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy. J Clin Oncol. 2017;35(26):3030-3038. doi: 10.1200/JCO.2016.70.6267.
Urruticoechea A, Rizwanullah M, Im SA, Sánchez Ruiz AC, Lang I, Tomasello G, et al. Final overall survival (OS) analysis of PHEREXA:
A randomized phase III trial of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy. J Clin Orthod. 2018 May 20;36(15_suppl):1013–1013. doi:10.1200/JCO.2018.36.15_suppl.1013.
Bischoff J, Barinoff J, Mundhenke C, Bauerschlag DO, Costa SD, Herr D, et al. A randomized phase II study to determine the efficacy
and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer
(E-VITA). Anticancer Drugs. 2019;30(4):394-401. doi: 10.1097/CAD.0000000000000722.
André F, O’Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, et al. Everolimus for women with trastuzumab-resistant, HER2-positive,
advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15(6):580-91.
doi: 10.1016/S1470-2045(14)70138-X.
Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124-30. doi:
1200/JCO.2008.21.4437.
Johnston SRD, Hegg R, Im SA, Park IH, Burdaeva O, Kurteva G, et al. Phase III, Randomized Study of Dual Human Epidermal Growth
Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal
Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE. J Clin Oncol.
;39(1):79-89. doi: 10.1200/JCO.20.01894.
Bian L, Xu BH, Di LJ, Wang T, Wang XJ, Jiao SC, et al. [Phase randomized controlled, multicenter, prospective study of recombinant anti-HER2 humanized monoclonal antibody (Cipterbin) combined with vinorelbine in patients with HER2 positive metastatic breast cancer: the HOPES Study]. Zhonghua Yi Xue Za Zhi. 2020;100(30):2351-2357. doi: 10.3760/cma.j.cn112137-20200116-00105.
Cortés J, Diéras V, Lorenzen S, Montemurro F, Riera-Knorrenschild J, Thuss-Patience P, et al. Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial. JAMA Oncol. 2020;6(8):1203-1209. doi: 10.1001/jamaoncol.2020.1796.
Harbeck N, Huang CS, Hurvitz S, Yeh DC, Shao Z, Im SA, et al. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet Oncol. 2016;17(3):357-366. doi: 10.1016/S1470-2045(15)00540-9.
Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, et al. A randomized phase II trial of trastuzumab plus capecitabine
versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and
taxanes: WJOG6110B/ELTOP. Breast. 2018;40:67-75. doi: 10.1016/j.breast.2018.04.010.
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with
hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol.
;21(6):763-775. doi: 10.1016/S1470-2045(20)30112-1.
Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(6):732-742. doi: 10.1016/S1470-2045(17)30312-1.
Haddad TC, He J, O’Sullivan CC, Chen B, Northfelt D, Dueck AC, et al. Randomized Phase II Trial of Capecitabine and Lapatinib with or
without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and
Chemotherapy: NCCTG N0733 (Alliance). Breast Cancer Res Treat. 2021;188(2):477-487. doi: 10.1007/s10549-021-06221-8.
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced
breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO). J Chemother. 2014;26(5):300-5. doi:
1179/1973947813Y.0000000147.
Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112(3):533-43. doi: 10.1007/s10549-007-9885-0.
von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, et al. Trastuzumab beyond progression in human epidermal
growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol. 2009;27(12):1999-2006. doi: 10.1200/JCO.2008.19.6618.
Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020 Oct;21(10):1283-1295. doi: 10.1016/S1470-2045(20)30465-4.
Martin M, Bonneterre J, Geyer CE Jr, Ito Y, Ro J, Lang I, et al. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer. 2013;49(18):3763-72. doi: 10.1016/j.
ejca.2013.07.142.
Harbeck N, Im SA, Barrios CH, Bonnefoi HR, Gralow J, Toi M, et al. Primary analysis of KAITLIN: A phase III study of trastuzumab
emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk
HER2-positive early breast cancer (EBC). J Clin Orthod. 2020;38(15_suppl):500–500. doi:10.1200/JCO.2020.38.15_suppl.500.
Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724-34. doi: 10.1056/NEJMoa1413513.
Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, et al. Overall survival benefit with lapatinib in combination
with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the
EGF104900 Study. J Clin Oncol. 2012;30(21):2585-92. doi: 10.1200/JCO.2011.35.6725.
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022;386(12):1143-1154. doi: 10.1056/NEJMoa2115022.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2023 Agustín Ciapponi, Ariel Bardach, Carla Colaci, Federico Rodríguez Cairoli, Fernando Argento, Ernesto Korbenfeld, Sebastián García Martí
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Cómo citar
